Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (20 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Research revenue
18
0
15
12
0
1
0
Collaboration and milestone revenue
47
1
7
7
0
0
0
Total revenue
64
1
21
18
0
1
0
Research and development
48
39
51
50
42
48
77
General and administrative
20
16
20
19
19
21
47
Changes in fair value of contingent consideration payable
0
0
0
0
0
0
4
Restructuring charges
2
0
0
0
2
0
0
Depreciation and amortization
2
2
2
2
2
2
2
Total operating expenses
72
57
72
71
65
70
130
Loss from operations
-7
-56
-51
-53
-64
-69
-130
Interest income
1
0
0
0
0
0
1
Interest expense
0
0
0
0
0
-1
-2
Loss on extinguishment of debt
0
0
0
0
0
0
-1
Change in fair value of warrant liability
0
-1
3
1
1
0
0
Other expense
0
1
0
0
0
0
0
Loss before income tax benefit
-7
-56
-48
-52
-63
-70
-132
Income tax benefit
0
1
4
3
4
1
0
Net loss
-7
-55
-44
-49
-60
-69
-132
Net loss attributable to common stockholders
-7
-55
-44
-49
0
0
0
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (36 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
30
26
34
44
24
69
Investments in marketable securities
n/a
78
30
65
38
128
145
Inventories
n/a
0
0
0
0
0
0
Receivable due from collaboration agreements
n/a
0
5
3
1
0
0
Prepaid expenses and other current assets
n/a
2
6
2
5
3
3
Total current assets
n/a
110
67
105
88
155
217
Investments in marketable securities
n/a
0
0
0
0
17
0
Property and equipment, less accumulated depreciation
n/a
3
2
5
4
3
6
In-process research & development
n/a
0
0
0
23
23
487
Goodwill
n/a
0
0
0
12
12
198
Other non-current assets
n/a
0
1
0
1
1
1
Total assets
n/a
113
70
110
128
210
908
Liabilities and owners' equity
Accounts payable and accrued expenses
n/a
8 8290000
10 9708000
9 8845000
10 10162000
16 16345000
32 32216000
Current portion of capital lease obligations
n/a
0 40000
0 0
0 0
0 0
0 0
0 0
Current portion of deferred revenue
n/a
7 6640000
0 0
0 0
0 0
0 0
0 0
Current portion of secured loan
n/a
1 1253000
1 1044000
0 398000
0 299000
4 3840000
0 0
Current portion of contingent consideration payable
n/a
0 0
0 0
0 0
0 0
0 0
41 41400000
Other current liabilities
n/a
0 0
9 8504000
0 0
0 0
0 0
0 0
Total current liabilities
n/a
16 16223000
19 19256000
9 9243000
10 10461000
20 20185000
74 73616000
Deferred reimbursements
n/a
26 25639000
19 18999000
30 30418000
37 36677000
37 36620000
36 35756000
Due to related party
n/a
0 0
0 0
0 0
0 0
0 0
42 41601000
Secured loan, less current portion
n/a
1 1044000
0 0
0 299000
14 14174000
11 10510000
0 0
Deferred tax liability
n/a
0 0
0 0
0 0
9 9186000
0 0
0 0
Contingent consideration payable, less current portion
n/a
0 0
0 0
0 0
11 10600000
11 10700000
233 232677000
Deferred tax liability
n/a
0 0
0 0
0 0
0 0
9 9186000
176 176219000
Other non-current liabilities
n/a
0 0
0 0
0 0
1 714000
1 588000
1 681000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
n/a
0 406000
0 407000
1 556000
1 679000
1 1015000
1 1306000
Additional paid-in capital
n/a
290 290248000
299 299285000
388 387539000
424 423593000
569 568743000
917 917454000
Unrealized gain/(loss) on available-for securities
n/a
0 -28000
0 4000
0 14000
0 1000
0 -132000
0 -115000
Warrants and Rights Outstanding
n/a
5 4712000
2 1948000
1 908000
0 0
0 0
9 8755000
Accumulated deficit
n/a
-226 -225692000
-270 -270104000
-319 -318889000
-379 -378522000
-447 -447448000
-580 -579566000
Total stockholders' equity
n/a
65 64934000
30 29592000
69 69220000
46 45751000
122 122178000
348 347834000
Total liabilities and stockholders' equity
n/a
113 112552000
70 69795000
110 110088000
128 127563000
210 209967000
908 908384000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Mar 13, 2013 n/a restated on Nov 30, -1 n/a restated on Mar 3, 2015 n/a restated on Feb 29, 2016 n/a restated on Aug 9, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (39 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
-7
-55
-44
-49
-60
-69
-132
Non-cash interest expense
0
0
0
0
0
0
0
Depreciation and amortization
2
2
2
2
2
2
2
Stock-based compensation
8
6
9
6
6
6
10
Restructuring charges
0
0
0
0
2
0
0
Change in fair value of warrant liability
0
1
-3
-1
-1
0
0
Non-cash changes in the fair value of contingent consideration payable
0
0
0
0
0
0
4
Loss on extinguishment of debt
0
0
0
0
0
0
1
Loss on disposal of asset
0
0
0
0
0
0
0
Receivable due from collaboration agreements
0
0
-5
2
2
1
0
Prepaid expenses and other current assets
0
0
-4
4
-3
2
0
Other non-current assets
0
0
0
0
0
0
-1
Accounts payable and accrued expenses
1
-1
1
-1
-1
6
15
Non-current liabilities
0
0
0
0
0
0
0
Deferred reimbursements
-48
32
-5
3
6
0
-1
Net cash used in operating activities
-43
-14
-49
-34
-46
-52
-100
Sale and redemption of marketable securities
132
95
98
83
83
56
290
Purchases of marketable securities
-98
-114
-51
-118
-57
-163
-290
Purchases of property and equipment
-2
0
-1
-4
-1
0
-5
Acquisitions, net of cash acquired
0
0
0
0
0
0
-141
Net cash used in investing activities
32
-19
46
-39
26
-107
-145
Proceeds from the issuance of common stock and warrants, net of issuance costs
0
45
0
80
15
136
243
Payments of secured loan agreement
0
-1
-1
-1
0
0
-15
Payment of capital lease
-1
0
0
0
0
0
0
Payments related to deferred financing
0
0
0
0
0
0
0
Proceeds from secured loan agreement
4
0
0
1
15
0
50
Purchase of vested restricted stock units
0
0
0
0
0
0
-2
Proceeds from exercise of stock options
0
0
0
2
0
4
11
Proceeds from exercise of warrants
0
0
0
0
0
0
4
Net cash provided by financing activities
3
44
-1
81
29
139
291
Net decrease in cash and cash equivalents
-9
10
-4
8
10
-20
45
Conversion of warrants to common stock
0
0
0
0
0
0
0
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 3, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,